Mitochondrial dysfUnction: a Key Player in Doxorubicin-induced Skeletal and Cardiac muscLE Damage

Inclusion criteria: * Age ≥ 18 years * Patients with large B-cell lymphoma or T-cell lymphoma scheduled for 6 full-dose cycles of 1st line immunochemotherapy with cyclophosphamide, doxorubicin, vincristine and prednisone with or without rituximab ((reversed) (R-)CHOP). * WHO-performance score 0-2. * Patients with sufficient Dutch writing and reading skills. * Written informed consent. Exclusion Criteria: * Contra-indications for 7T MR scanning, including patients with a non-MRI compatible pacemaker, cochlear implant or neurostimulator; patients with non-MR compatible metallic implants in their eye, spine, thorax or abdomen; patients with a non-MR compatible aneurysm clip in their brain; patients with claustrophobia, and/or severe obesity. * Any circumstances that would impede adherence to study requirements or ability to give informed consent. * Medical disorders affecting mitochondrial function; e.g., spinal muscular atrophy. * (Other) relevant medical disorders; e.g., comorbidities affecting exercise tolerance. * Being under examination for non-diagnosed disease at the time of investigation.